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Abstract
Introduction: Prevalence of insulin resistance and the metabolic syndrome has been reported to be high in
rheumatoid arthritis (RA) patients. Tumor necrosis factor (TNF), a pro-inflammatory cytokine with a major
pathogenetic role in RA, may promote insulin resistance by inducing Ser312 phosphorylation (p-Ser312) of insulin
receptor substrate (IRS)-1 and downregulating phosphorylated (p-)AKT. We examined whether anti-TNF therapy
improves insulin resistance in RA patients and assessed changes in the insulin signaling cascade.
Methods: Prospective study of RA patients receiving anti-TNF agents (infliximab, n = 49, adalimumab, n = 11, or
etanercept, n = 1) due to high disease activity score in 28 joints (DAS28 > 5.1). A complete biochemical profile was
obtained at weeks 0 and 12 of treatment. Insulin resistance, insulin sensitivity and pancreatic beta cell function
were measured by the Homeostasis Model Assessment (HOMA-IR), the Quantitative Insulin Sensitivity Check Index
(QUICKI) and the HOMA-B respectively. Protein extracts from peripheral blood mononuclear cells were assayed by
western blot for p-Ser312 IRS-1 and p-AKT. RA patients treated with abatacept (CTLA4.Ig) were used as a control
group for insulin signaling studies.
Results: At study entry, RA patients with high insulin resistance (HOMA-IR above median) had significantly higher
mean DAS28 (P = 0.011), serum triglycerides (P = 0.015), and systolic blood pressure levels (P = 0.024) than patients
with low insulin resistance. After 12 weeks of anti-TNF therapy, patients with high insulin resistance demonstrated
significant reduction in HOMA-IR (P < 0.001), HOMA-B (P = 0.001), serum triglycerides (P = 0.039), and increase in
QUICKI (P < 0.001) and serum HDL-C (P = 0.022). Western blot analysis in seven active RA patients with high insulin
resistance showed reduction in p-Ser312 IRS-1 (P = 0.043) and increase in p-AKT (P = 0.001) over the study period.
In contrast, the effect of CTLA4.Ig on p-Ser312 IRS-1 and p-AKT levels was variable.
Conclusions: Anti-TNF therapy improved insulin sensitivity and reversed defects in the insulin signaling cascade in
RA patients with active disease and high insulin resistance. The impact of these biochemical changes in modifying
cardiovascular disease burden in active RA patients remains to be seen.
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Introduction
Insulin resistance is a key feature of obesity, metabolic
syndrome, and type 2 diabetes mellitus (T2DM). Insulin
signaling is a complex process; binding of insulin to its
receptor induces both auto-phosphorylation and phos-
phorylation of tyrosine residues on insulin receptor sub-
strate (IRS) proteins, the most prominent being IRS-1
and IRS-2, thus initiating the intracellular signaling cas-
cade [1,2]. IRS-1 and IRS-2 mediate their metabolic
effects through the phosphatidyl-inositol 3-kinase (PI-
3K) pathway, which results in activation of AKT and
other downstream effector molecules. IRS-1 may be
more closely linked to glucose homeostasis, whereas
IRS-2 is primarily involved in lipid metabolism [3]. Insu-
lin signaling may also activate the mitogen activated
protein kinase (MAPK) isoforms ERK1 and ERK2,
through Grb/Sos and ras. This pathway mediates the
mitogenic and pro-inflammatory responses of insulin
signaling while it does not affect glucose homeostasis
[4]. In obese patients with insulin resistance, the path-
ways leading to PI-3K activation are blocked, whereas
the MAPK pathway remains active or even hypersensi-
tive [5].
Inflammation and insulin resistance are closely linked
and inflammatory cytokines such as tumor necrosis factor
(TNF), interleukin (IL)-6, IL-1 and IL-8 may inhibit insulin
signaling by multiple mechanisms [6]. TNF induces phos-
phorylation of IRS-1 at serine instead of tyrosine residues
and promotes insulin resistance [7,8]. Both IL-6 and TNF
may inhibit the transcription of IRS-1 and glucose trans-
porter (GLUT)-4 genes, thus reducing glucose transport
and enhancing insulin resistance in obese patients [9].
Patients with rheumatoid arthritis (RA) are at increased
risk for cardiovascular disease [10] independently of tradi-
tional vascular risk factors [11]. Cohort studies have
demonstrated increased prevalence of metabolic syndrome
in patients with RA, correlating with disease activity and
markers of atherosclerosis [12-14]. RA patients are also at
increased risk for T2DM compared with non-rheumatic
controls (adjusted hazard ratio 1.5) [15], and pancreatic
beta cell function is associated with disease activity and
cumulative dose of glucocorticoids [14].
Observational studies suggest that anti-TNF therapy
improves disease activity and may reduce cardiovascular
events in RA patients (age-sex adjusted rate ratio 0.46)
[16,17]. This effect is thought to be mediated by reduc-
tion in insulin resistance and metabolic syndrome com-
ponents demonstrated in patients treated with TNF
blockade [18-22]. However, the results of the aforemen-
tioned studies are limited by the inclusion of a small
number of RA patients and the lack of any mechanistic
insights to the molecular effects of TNF blockade on
insulin signaling.
To this end, we set out a 12-week prospective study in
patients with RA, who were receiving anti-TNF agents due
to active disease, to assess changes in insulin resistance/
sensitivity, serum lipoproteins, and activation of the insulin
receptor signaling cascade. Anti-TNF therapy resulted in
significant improvement in insulin resistance/sensitivity
and pancreatic beta cell function in RA patients with high
baseline insulin resistance. Importantly, our studies in per-
ipheral blood mononuclear cells from RA patients demon-
strated reduction in IRS-1 serine phosphorylation and
increase in AKT phosphorylation following anti-TNF ther-




We prospectively studied patients with RA who were
started on anti-TNF agents due to high disease activity,
defined by a disease activity score in 28 joints (DAS28)
> 5.1 despite treatment with disease-modifying anti-
rheumatic drugs (DMARDs) [23]. Patients fulfilled the
American College of Rheumatology 1987 classification
criteria for RA [24]. Patients aged < 18 years or with
history of DM were excluded. Anti-TNF agents (inflixi-
mab, adalimumab or etanercept) were given at approved
standard doses. The dosage of background DMARDs
and glucocorticoids, as well as of anti-hypertensive and
lipid-lowering treatments remained stable during the
study period. Detailed medical and drug history was
obtained, and the use of tobacco was recorded. Disease
activity (DAS28) was assessed at baseline and after 12
weeks of treatment [25]. Coronary heart disease was
defined as presence of any of the following: angina pec-
toris, myocardial infarction or coronary revascularization
procedures (bypass grafting, percutaneous coronary
intervention). As a control group, we consecutively
enrolled seven patients with RA who were started on
abatacept (CTLA4.Ig), another class of biologic therapy
which targets T-cell costimulation rather than TNF, due
to high disease activity (DAS28 > 5.1). All patients
signed informed consent forms, and the study protocol
was approved by the University Hospital of Heraklion
Ethics Committee (13/12/99).
Assessment of insulin resistance/sensitivity and other
metabolic parameters
Blood was drawn after 12-hour overnight fasting. Serum
concentrations of total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), and triglycerides (TG)
were measured using an automated chemistry analyzer
(Olympus AU-600, Tokyo, Japan). Low-density lipopro-
tein cholesterol (LDL-C) was calculated according to the
Friedewald formula except for samples with serum TG >
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400 mg/dl (4.5 mmol/L). Apolipoprotein (apo)-A, apo-B
and lipoprotein a (Lpa) were analyzed by immunonephe-
lometry (BN II analyzer, Eschborn, Germany). Plasma
glucose concentration was determined by standard enzy-
matic colorimetric assay (Roche Diagnostics, Mannheim,
Germany). C-reactive protein (CRP) was measured by
immune nephelometry (BN II analyzer, Eschborn, Ger-
many) and erythrocyte sedimentation rate (ESR) by an
automated analyzer (Ves-matic 20, Florence, Italy).
Serum insulin was determined by chemiluminescent
microparticle immunoassay (ARCHITECT Insulin
Reagent Kit, 8K41, Abbott Diagnostics, Lake Forest, Illi-
nois, USA)
While the hyperinsulinemic euglycemic clamp techni-
que is the gold standard for evaluating insulin sensitiv-
ity, the Homeostasis Model Assessment (HOMA) for
insulin resistance and the Quantitative Insulin Sensitivity
Check Index (QUICKI) are widely used as noninvasive
surrogate markers of insulin resistance and sensitivity,
respectively [26,27]. Pancreatic beta cell function was
assessed by the HOMA for beta cell function (HOMA-
B) [28]. We used the National Cholesterol Education
Program (NCEP) Adult Treatment Panel (ATP) III cri-
teria for metabolic syndrome [29].
Isolation of peripheral blood mononuclear cells (PBMCs)
and protein extracts
PBMCs were isolated by Ficoll-Histopaque (Sigma-
Aldrich, St. Louis, MO, USA) density-gradient centrifu-
gation of heparinized venous blood. PBMCs were lysed
with RIPA buffer containing 50 mM Tris-HCl, pH 7.2,
150 mM sodium chloride, 1% NP-40, 12 mM sodium
deoxycholate, 3 mM sodium dodecyl sulfate, 4 mM
sodium azide, 0.57 mM phenylmethysulfonyl fluoride
and complete protease inhibitor cocktail. Protein con-
centrations were determined by Bradford protein assay
(Bio-Rad laboratories, Inc, Hercules, CA, USA).
Western blot analysis
Proteins were separated by 8% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to nitrocellulose membrane (Whatman,
Schwerte, Germany). Membranes were probed overnight
with anti-phospho-IRS1-Ser312 (Upstate, Lake Placid,
NY, USA) and anti-phospho-Akt-Ser473 (Cell Signalling,
Frankfurt, Germany) monoclonal antibodies. Blots were
also probed with anti-b-actin (Santa Cruz, CA, USA) to
control for total protein content. The secondary antibo-
dies horseradish peroxidase (HRP)-conjugated anti-
mouse IgG and anti-rabbit IgG were used (Santa Cruz,
CA, USA). Enhanced chemiluminescence (ECL) from
Thermo Scientific (Vantaa, Finland) was used for detec-
tion, and densitometry analysis was performed with
Image J program.
Statistical analysis
Results are expressed as the mean and 95% confidence
interval (95% CI) or as proportions. Parameters showing
abnormal distribution were logarithmically transformed.
In a post-hoc analysis, we used the median HOMA-IR
value (3.18) to define high insulin resistance, and we com-
pared the recorded variables in RA patients with high ver-
sus low insulin resistance using the independent samples
t-test (continuous variables) or the chi-squared test (cate-
gorical variables). The Pearson’s test was used for bivariate
correlation analysis. Logistic regression (backward selec-
tion) was further performed to calculate odds ratios (ORs)
for high versus low HOMA-IR according to demographic
and lifestyle (gender, age, tobacco use), metabolic (obesity,
hypertension, use of statins, metabolic syndrome), and
clinical parameters, including the DAS28, health assess-
ment questionnaire (HAQ), CRP, and RA treatment mod-
ality (glucocorticoids, methotrexate). Changes in recorded
parameters between baseline and the end of the 12-week
study period were analyzed by paired t-test or the Wil-
coxon signed ranks test as appropriate. To address
whether the effect of anti-TNF treatment on insulin resis-
tance is confounded by changes in disease activity, we per-
formed repeated measures analysis of variance (ANOVA)
entering HOMA-IR values at baseline and at 12 weeks
after treatment as dependent variables (within-subject
variables), the insulin resistance group (high versus low
baseline HOMA-IR) as grouping factor (between-subject
variable), and the change in DAS28 score as a covariate.
P values (two-tailed) < 0.05 were considered statistically
significant. SPSS software version 18.0 (SPSS, Inc) was
used for the statistical calculations.
Results
Patients’ clinical characteristics at baseline
We prospectively studied 61 patients with RA (43 women)
of mean age 60 years and mean disease duration 7.2 years
(Table 1). All patients had active disease with mean
DAS28 score 5.8 and they were started on one of the fol-
lowing anti-TNF agents: infliximab (n = 49), adalimumab
(n = 11), or etanercept (n = 1). Fifty six patients (92%)
were on single (n = 36) or combination (n = 20) therapy
with DMARDs, including methotrexate (n = 42), lefluno-
mide (n = 15), and hydroxychloroquine (n = 17). Thirteen
patients were on glucocorticoids. Patients treated with
abatacept had comparable demographic and clinical char-
acteristics and metabolic profiles to patients treated with
anti-TNFagents (data not shown).
Association of clinical and metabolic parameters with
insulin resistance in RA patients
We used the median HOMA-IR at baseline to assign
patients to the low (HOMA-IR ≤ 3.18, n = 31) and high
(HOMA-IR > 3.18, n = 30) insulin resistance group.
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Table 1 Baseline characteristics of the rheumatoid arthritis patients included in the study*
Insulin resistance





Age (years) 60 (57, 63) 58 (54, 63) 62 (58, 67) 0.157
Gender (% female) 70 74 63 0.360
Disease duration (years) 7.2 (5.6, 9.3) 6.9 (4.8, 10.1) 7.5 (5.2, 10.9) 0.727
DAS28 5.8 (5.5, 6.1) 5.4 (5.1, 5.8) 6.3 (5.8, 6.7) 0.011
HAQ 1.0 (0.8, 1.2) 0.9 (0.6, 1.1) 1.1 (0.9, 1.4) 0.129
C-reactive protein (mg/dl) 1.4 (0.8, 2.1) 1.2 (0.2, 2.1) 1.7 (0.7, 2.6) 0.134
ESR (mm/hr) 35 (29, 40) 33 (24, 42) 36 (28, 44) 0.559
Insulin (μIU/ml) 13.5 (10.4, 17.4) 7.0 (5.1, 9.5) 26.7 (21.0, 33.8) < 0.001
FBG (mg/dl) 96 (89, 103) 87 (80, 93) 107 (95, 119) < 0.001
HOMA-IR § 3.2 (2.4, 4.3) 1.5 (1.1, 2.0) 7.0 (5.2, 9.4) < 0.001
HOMA-B § 159 (122, 207) 123 (77, 195) 210 (168, 263) 0.013
QUICKI 0.33 (0.31, 0.34) 0.36 (0.34, 0.39) 0.29 (0.28, 0.30) < 0.001
TC (mg/dl) 221 (206, 235) 226 (204, 247) 216 (195, 236) 0.471
HDL-C (mg/dl) 54 (50, 57) 56 (52, 61) 51 (46, 57) 0.095
LDL-C (mg/dl) 137 (125, 150) 144 (126, 162) 131 (114, 148) 0.278
TC/HDL-C 4.3 (3.9, 4.6) 4.1 (3.7, 4.5) 4.4 (3.9, 4.9) 0.399
LDL-C/HDL-C 2.7 (2.4, 2.9) 2.6 (2.3, 3.0) 2.7 (2.3, 3.1) 0.868
Triglycerides (mg/dl) 151 (132, 171) 129 (105, 152) 175 (144, 206) 0.015
Lpa (mg/dl) 12.8 (9.5, 17.1) 10.1 (6.6, 15.4) 16.4 (10.9, 24.8) 0.130
apoA (mg/dl) 162 (155, 169) 168 (158, 177) 156 (146, 166) 0.079
apoB (mg/dl) 99 (92, 107) 100 (88, 112) 99 (89, 109) 0.762
apoB/apoA 0.63 (0.58, 0.69) 0.61 (0.52, 0.70) 0.66 (0.57, 0.74) 0.364
Homocysteine (μmol/l) 17.5 (15.7, 19.3) 17.8 (15.1, 20.5) 17.2 (14.6, 19.9) 0.584
Body weight (kg) 75 (71, 79) 73 (68, 78) 77 (7, 83) 0.203
Body mass index (kg/m2) 29.1 (27.5, 30.7) 28.6 (26.2, 30.9) 29.7 (27.4, 32.1) 0.371
Waist circumference (cm) 101 (97, 105) 100 (94, 106) 102 (97, 107) 0.207
SBP (mmHg) 127 (123, 131) 125 (118, 132) 130 (125, 134) 0.024
DBP (mmHg) 77 (75, 79) 78 (74, 81) 76 (73, 79) 0.672
Metabolic syndrome (%) ** 41 19 63 0.001
Statin use (%) 19 13 24 0.333
Tobacco use (%) 19 23 14 0.506
Coronary heart disease (%) 14 10 17 0.472
Hypertension (%) 61 58 63 0.795
Antihypertensive therapy (%) 46 48 43 0.799
MTX (%) 69 65 73 0.582
MTX dose (mg/week) 14.8 (14.0, 15.7) 15.9 (14.7, 17.1) 13.9 (12.7, 15.0) 0.033
GC (%) 21 19 23 0.762
GC dose (mg/day) 8.8 (5.6, 12.1) 7.9 (5.3, 10.5) 9.6 (3.0, 16.2) 0.705
* Except where indicated otherwise, values are the mean (95% confidence interval)
† The median Homeostasis Model Assessment for insulin resistance (HOMA-IR) value at baseline was used to assign patients into low (HOMA-IR ≤ 3.18, n = 31) or
high (HOMA-IR > 3.18, n = 30) insulin resistance group
# P value for the comparison between low and high insulin resistance groups
§ Statistical comparisons were performed using log transformed values. Values represent the geometric mean
** According to the Adult Treatment Panel (ATP) III criteria for the definition of the metabolic syndrome
DAS28: disease activity score of 28 joints; HAQ: health assessment questionnaire; ESR: erythrocyte sedimentation rate; FBG: fasting blood glucose; QUICKI:
Quantitative Insulin Sensitivity Check Index; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lpa:
lipoprotein a; apo: apolipoprotein; SBP: systolic blood pressure; DBP: diastolic blood pressure; MTX: methotrexate; GC: glucocorticoids.
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Patients in the high insulin resistance group had higher
mean disease activity (P = 0.011), fasting serum insulin (P
< 0.001), plasma glucose (P < 0.001), triglycerides (P =
0.015), and systolic blood pressure levels (P = 0.024) than
patients with low insulin resistance (Table 1). Metabolic
syndrome was more frequent in RA patients with high
insulin resistance (63% versus 19% in those with low
insulin resistance, P = 0.001). In accordance with pre-
vious reports [30], we found significantly increased pan-
creatic beta cell function, assessed by the HOMA-B
index, in RA patients with high insulin resistance.
By using a cut-off of HOMA-IR > 2.0 [31], 74% (n = 45)
of RA patients were classified as having insulin resistance.
Patients with HOMA-IR > 2.0 at baseline had higher
serum insulin (P < 0.001), HOMA-B (P < 0.001), and tri-
glycerides (P = 0.014), and lower QUICKI (P < 0.001)
than those with HOMA-IR ≤ 2.0. RA patients with insu-
lin resistance had a trend for higher DAS28 (P = 0.105)
and significantly higher HAQ (P = 0.037). Fasting plasma
glucose levels were not significantly different between the
two groups, although 61% in patients with insulin resis-
tance versus 6% in those without insulin resistance had
metabolic syndrome (P = 0.001) (data not shown).
HOMA-IR correlated with DAS28 (r = 0.31, P = 0.016)
and fasting triglycerides (r = 0.38, P = 0.003), and
HOMA-B correlated with body mass index (BMI) (r =
0.28, P = 0.035) (data not shown). In multivariate regres-
sion analysis, presence of the metabolic syndrome and
DAS28 score > 6.86 (75th percentile) were independent
predictors for high insulin resistance with ORs of 10.8
(95% CI 2.8 to 42.6, P = 0.001) and 6.4 (95% CI 1.2 to
32.9, P = 0.027), respectively. BMI > 30 kg/m2 was asso-
ciated with an OR of 3.8 (95% CI 1.1 to 12.4, P = 0.030)
for increased pancreatic beta cell function.
Anti-TNF therapy improves insulin resistance/sensitivity,
pancreatic beta cell function, and metabolic parameters
in patients with active RA and high insulin resistance
Patients with high baseline insulin resistance demon-
strated significant improvement in DAS28 (P = 0.013),
HAQ (P = 0.012), and CRP (P = 0.007) after 12 weeks of
treatment with anti-TNF agents (Table 2). A similar
trend was observed in patients with lower baseline insulin
resistance, yet only reduction in HAQ was statistically
significant (P = 0.018). Anti-TNF therapy resulted in sig-
nificant improvement in HOMA-IR (P < 0.001), QUICKI
Table 2 Effect of anti-TNFa treatment on clinical and metabolic profile in rheumatoid arthritis RA patients with low
and high baseline insulin resistance*
Insulin resistance
Low (n = 31) P value† High (n = 30) P value
DAS28 -0.52 (-1.20, 0.16) 0.127 -0.57 (-1.01, -0.13) 0.013
HAQ -0.23 (-0.42, -0.05) 0.018 -0.26 (-0.45, -0.06) 0.012
ESR -3.04 (-15.3, 9.20) 0.611 -1.04 (-7.91, 5.84) 0.760
C-reactive protein # -0.69 (-1.91, 0.53) 0.147 -0.83 (-1.72, 0.05) 0.007
TC -5.92 (-20.0, 8.21) 0.395 8.63 (-6.53, 23.8) 0.253
Triglycerides 12.3 (-16.7, 41.3) 0.390 -24.5 (-47.7, -1.31) 0.039
HDL-C 0.75 (-3.25, 4.75) 0.701 4.21 (0.65, 7.78) 0.022
LDL-C -9.78 (-20.2, 0.64) 0.065 9.15 (-3.94, 22.2) 0.163
TC/HDL-C -0.08 (-0.35, 0.18) 0.511 -0.12 (-0.44, 0.19) 0.421
LDL-C/HDL-C -0.14 (-0.31, 0.03) 0.110 0.01 (-0.25, 0.27) 0.929
Lpa # -4.38 (-9.31, 0.55) 0.147 0.25 (-7.72, 8.22) 0.200
apoA -6.12 (-17.3, 5.03) 0.262 5.64 (-3.94, 15.2) 0.236
apoB -2.99 (-13.0, 6.99) 0.534 2.09 (-4.81, 8.99) 0.537
Homocysteine # -2.66 (-5.88, 0.57) 0.122 2.53 (-0.35, 5.41) 0.039
FBG 1.08 (-1.02, 1.18) 0.117 -19.7 (-34.8, -4.61) 0.016
HOMA-IR # 1.87 (-0.34, 4.09) 0.197 -5.68 (-8.86, -2.50) < 0.001
HOMA-B # -130 (-375, 116) 0.446 -148 (-244, -46) 0.001
QUICKI # -0.01 (-0.03, 0.01) 0.264 0.07 (0.04, 0.09) < 0.001
Insulin # 5.80 (-1.12, 12.7) 0.301 -21.7 (-33.8, -9.62) < 0.001
Values are the mean (95% confidence interval)
* The median Homeostasis Model Assessment for insulin resistance (HOMA-IR) value at baseline was used to assign patients into low (HOMA-IR ≤ 3.18, n = 31) or
high (HOMA-IR > 3.18, n = 30) insulin resistance group
† Paired t-test for comparison of values between baseline and after 12 weeks of anti-TNF treatment
# Statistical comparisons were performed using log transformed values
DAS28: disease activity score of 28 joints; HAQ: health assessment questionnaire; ESR: erythrocyte sedimentation rate; TC: total cholesterol; HDL-C: high-density
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lpa: lipoprotein a; apo: apolipoprotein; FBG: fasting blood glucose; QUICKI: Quantitative Insulin
Sensitivity Check Index.
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(P < 0.001), and HOMA-B (P = 0.001) only in RA
patients with high baseline insulin resistance (Table 2).
In these patients, significant decreases in fasting plasma
glucose (P = 0.016), serum insulin (P < 0.001), and serum
triglycerides (P = 0.039), and increase in serum HDL-C
(P = 0.022) levels were observed.
We repeated the analysis in RA patients with baseline
HOMA-IR ≤ 2.0 (n = 16) or > 2.0 (n = 45). Anti-TNF
treatment reduced DAS28 (P = 0.007), HAQ (P = 0.002),
and CRP (P = 0.002) in patients with insulin resistance
but not in those with HOMA-IR ≤ 2.0 (data not shown).
TNF blockade resulted in significant reduction in serum
insulin (P < 0.001) and improvements in HOMA-IR (P =
0.001), HOMA-B (P = 0.001), and QUICKI (P = 0.001) in
patients with HOMA-IR > 2.0. In contrast, there were no
significant changes in serum triglycerides (P = 0.058),
HDL-C (P = 0.101), homocysteine (P = 0.312) and blood
glucose (P = 0.166). These findings suggest that the meta-
bolic effects of anti-TNF treatment may be more pro-
nounced in RA patients with very high insulin resistance
levels compared to those with low-level or no insulin
resistance.
We next examined whether changes in insulin resis-
tance/sensitivity and pancreatic beta cell function corre-
lated with changes in RA disease activity. Significant
improvements in the HOMA-IR, QUICKI, and HOMA-B
indices were found in RA patients with high baseline
insulin resistance irrespective of their clinical response
according to the European League Against Rheumatism
(EULAR) criteria (data not shown). In addition, repeated
measures ANOVA revealed a significant effect of anti-
TNF treatment (F test = 11.89, P = 0.001) and of the
interaction of anti-TNF treatment with baseline insulin
resistance group (F test = 24.68, P < 0.001) on HOMA-
IR. Conversely, the interaction of anti-TNF treatment
with the change in DAS28 had no significant impact on
HOMA-IR (F test = 0.06, P = 0.810), suggesting that the
effect of anti-TNF treatment on insulin resistance is not
confounded by improvement in disease activity.
Anti-TNF therapy reduces IRS-1 phosphorylation at Ser312
TNF may compromise insulin signaling by induction of
serine 312 (Ser312) phosphorylation of IRS-1 [7,32]. Based
on our findings of improved insulin resistance in patients
with active RA following treatment with anti-TNF agents,
we examined whether this effect is associated with altered
IRS-1 phosphorylation. We used PBMCs, which provide a
useful tool to determine alterations in the insulin signaling
cascade in vivo as they include all of the signaling proteins
present in insulin target tissues [33,34]. We purified total
protein extracts from PBMCs of seven randomly selected
RA patients at weeks 0 and 12 of anti-TNF therapy, and
we quantified IRS-1 Ser312 phosphorylation by western
blot. At study entry, all patients had active disease with
median DAS28 7.4 (range 5.6 to 9.0), and high insulin
resistance with median HOMA-IR 7.6 (range 3.1 to 10.3).
At week 12, all but one patient demonstrated reduction in
IRS-1 phosphorylation (Figure 1A). Phosphorylated IRS-1
normalized for b-actin protein expression was significantly
reduced from 0.96 (arbitrary units) at week 0 to 0.57 at
week 12 (Wilcoxon signed ranks test, P = 0.043) (Figure
1B). Both DAS28 and HOMA-IR improved over the study
period (Figures 1C, D). We found no correlation between
longitudinal changes in HOMA-IR and IRS-1 Ser312 phos-
phorylation levels.
Anti-TNF therapy increases AKT phosphorylation
IRS-1 mediates its metabolic effects through the PI-3K
pathway which results in phosphorylation of AKT and
other downstream molecules [32]. TNF-induced insulin
resistance involves inhibition of AKT through a ceramide-
activated protein-phosphatase (PP) 2A [35]. Individuals
with insulin resistance display reduced insulin stimulation
of the PI-3K pathway [5], and insulin-stimulated AKT
kinase activity is reduced in patients with T2DM [36,37].
Therefore, we measured phosphorylated AKT levels in
protein extracts from PBMCs of RA patients at weeks 0
and 12 of anti-TNF therapy. Phosphorylated AKT levels,
normalized for b-actin, increased in all seven RA patients
(Figure 1E) from a median 0.24 at week 0 to 0.94 at week
12 (P = 0.001) (Figure 1F). We found no correlation
between longitudinal changes in HOMA-IR or IRS-1
Ser312 phosphorylation and AKT phosphorylation levels.
Improvement in RA disease activity following therapy
with CTLA4.Ig does not correlate with changes in insulin
resistance, IRS-1 and AKT phosphorylation
To assess the specificity of the effect of TNF blockade
on insulin resistance, we prospectively studied seven RA
patients (median age 63 years, median disease duration
13 years) with high disease activity (median DAS28
5.92) treated with abatacept (CTLA4.Ig), a biologic
agent that targets T-cell co-stimulation. All patients
were receiving DMARDs (five on methotrexate, two on
leflunomide), and three patients were receiving low-dose
glucocorticoids. At baseline, three patients had low insu-
lin resistance (median HOMA-IR 1.16, range 0.87 to
1.91), and four patients had high insulin resistance
(median HOMA-IR 5.34, range 3.45 to 8.85).
At week 12 of abatacept treatment, disease activity was
reduced in all seven RA patients (Wilcoxon signed ranks
test, P = 0.046) (Figure 2A). Insulin resistance followed a
variable trend, and HOMA-IR increased in three patients
(two with low baseline insulin resistance), remained
stable in one patient, and decreased in three patients
(two with high baseline insulin resistance) (Figure 2B).
Similarly, HOMA-B was not significantly altered during
the study period (data not shown).
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Figure 1 Anti-TNF treatment decreases insulin receptor substrate (IRS)-1 Ser312 phosphorylation and increases AKT phosphorylation in
patients with active rheumatoid arthritis (RA) and high insulin resistance. (A) Seven patients with active RA received anti-TNF treatment for
12 weeks. Protein extracts from PBMCs were analyzed by western blotting for the Ser312-phosphorylated form of IRS-1 at weeks 0 and 12 of
treatment. All but one patient demonstrated decrease in IRS-1 phosphorylation at Ser312. (B) Quantitative analysis (protein densitometry) showed
that median phosphorylated IRS-1 normalized for b-actin levels were reduced from 0.96 to 0.57 (arbitrary units) (Wilcoxon signed ranks test, P =
0.043). (C) Decrease in disease activity following anti-TNF treatment (from median DAS28 7.4 to 6.3, P = 0.049). (D) Improvement in insulin
resistance following anti-TNF treatment (from median HOMA-IR 7.6 to 3.6, P = 0.028). (E) Protein extracts from peripheral blood mononuclear
cells (n = 7 RA patients) were analyzed by western blotting for Ser473- phosphorylated AKT at weeks 0 and 12 of anti-TNF therapy. (F)
Phosphorylated AKT levels, normalized for b-actin, increased in all RA patients from a median 0.24 (arbitrary units) at week 0 to 0.94 at week 12
(P = 0.001).
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Figure 2 Variable effect of CTLA4.Ig (abatacept) treatment on insulin receptor substrate (IRS)-1 and AKT phosphorylation in patients
with rheumatoid arthritis (RA). (A) Improvement in disease activity in RA patients (n = 7) following treatment with abatacept for 12 weeks,
from median disease activity score in 28 joints (DAS28) 5.9 to 4.8 (P = 0.046, Wilcoxon signed ranks test). (B) Treatment with abatacept had
variable effects on the Homeostasis Model Assessment for insulin resistance (HOMA-IR) in RA patients with low or high baseline insulin
resistance. (C) Protein extracts from periperhal blood mononuclear cells of the RA patients were analyzed by western blotting for the Ser312 and
Ser473- phosphorylated forms of insulin resistance substrate (IRS)-1 and AKT, respectively, at baseline and after 12 weeks treatment with
abatacept. (D) Quantitative analysis of p-Ser321 IRS-1 normalized to b-actin expression showed no significant change following treatment with
abatacept. (E) Variable trend in p-AKT levels from baseline to week 12 of treatment with abatacept in RA patients with low or high baseline
insulin resistance.
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To examine the effect of CTLA4.Ig treatment on the
insulin signaling cascade, we measured the levels of
Ser312-phosphorylated IRS-1 and phosphorylated AKT
(p-AKT) in protein extracts from PBMCs (Figure 2C).
We found no significant change in p-Ser321 IRS-1 or in
p-AKT levels in RA patients with either low or high
baseline insulin resistance (Figure 2D, E). We found no
correlation between changes in HOMA-IR and IRS-1 or
AKT phosphorylation levels.
Discussion
We evaluated the outcome on insulin resistance and
other metabolic parameters among 61 patients with
active RA disease, after 12 weeks of treatment with anti-
TNF agents. In a subset of patients, we also examined
the effect of TNF blockade on the phosphorylation sta-
tus of IRS-1 and AKT, which are major mediators of
insulin signaling. Our findings suggest that treatment
with anti-TNF agents may improve insulin resistance
and sensitivity in RA patients with active disease and
high insulin resistance, and this effect correlates with
reduced levels of the insulin-resistant Ser312-phosphory-
lated form of IRS-1 and increased levels of activated/
phosphorylated AKT.
Insulin resistance constitutes a major mechanism in
the pathophysiology of metabolic syndrome [38]. In our
cohort of patients with active RA, those with high insu-
lin resistance had significantly higher fasting plasma glu-
cose, serum triglycerides, and systolic blood pressure
levels than their counterparts in the low insulin resis-
tance group. Accordingly, patients with metabolic syn-
drome had an OR of 10.8 for high insulin resistance,
independent of the effect of other parameters.
In patients with RA, insulin resistance has been shown
to correlate both with anthropometric parameters
(abdominal obesity) and high disease activity [13,14].
We found that RA patients with high insulin resistance
had significantly higher DAS28 values than those with
low insulin resistance, and in multivariate analysis,
patients in the upper quartile of disease activity (DAS28
> 6.86) had more than six times increased risk (OR 6.4)
for high insulin resistance. This is in agreement with
our previous result of increased prevalence of metabolic
syndrome in RA patients with moderate or high disease
activity (OR 9.2 for DAS28 > 3.2) [12], and corroborates
the link between inflammation and insulin resistance in
chronic inflammatory disorders.
Previous studies have demonstrated that treatment
with TNF antagonists improves insulin sensitivity in RA
[18-22]. We further corroborate these results by examin-
ing the metabolic effects of anti-TNF therapy in a larger
cohort of 61 patients with active RA. Among patients
with high insulin resistance at baseline, treatment with
anti-TNF agents for 12 weeks resulted in significant
improvement in insulin sensitivity as evidenced by
reduction in the HOMA-IR and increase in the QUICKI
indices. Of note, serum triglycerides were reduced by an
average 24.5 mg/dl, and HDL-C levels were increased by
an average 4.2 mg/dl. Our findings agree with those of
Kiortsis, et al. [20] who reported significant decrease in
HOMA-IR and increase in QUICKI among patients
with RA and ankylosing spondylitis in the highest tertile
of insulin resistance, suggesting that this subset of
patients may benefit most from anti-TNF therapy. In
accordance with the results of previous studies
[18-20,22], we found no correlation between changes in
HOMA-IR and fasting insulin levels with improvements
in disease activity or CRP level.
We found that treatment with anti-TNF agents
resulted in significant reduction in the HOMA-B index
of pancreatic beta cell function in RA patients with high
baseline insulin resistance. This could be explained by
the therapy-driven reduction in the inflammatory bur-
den of the disease and the insulin resistance levels, thus
resulting in reduced compensatory beta cell hyperfunc-
tion. Whether this effect could lead to preservation of
beta cell function in the long term is currently
unknown. Intriguingly, a recent epidemiological study
found that among patients with RA or psoriasis, the
adjusted risk of new-onset DM was lower for individuals
on TNF inhibitor (adjusted hazard ratio 0.62) compared
with initiation of other non-biologic DMARDs [39].
TNF may impair insulin signaling at the level of the
IRS proteins, and the Ser307 (or Ser312 in humans) resi-
due in IRS-1 has been identified as a site for the inhibi-
tory effects of TNF, with p38 MAPK and inhibitor kB
kinase being involved in the phosphorylation of this
residue [7,8,32]. TNF mediates insulin resistance by
inhibition of AKT activity through a ceramide-activated
protein-phosphatase (PP) 2A [35]. Since anti-TNF ther-
apy significantly reduced HOMA-IR in patients with
active RA and high insulin resistance, we examined the
extent to which the aforementioned biochemical effects
are affected by TNF inhibition. Our western blot assays
demonstrated significant reduction in p-Ser312 IRS-1
and increase in p-AKT levels, associated with reduction
in HOMA-IR in patients with active RA and high base-
line insulin resistance. These alterations were consistent
in all but one patient in our study and their magnitude
did not correlate with the degree of improvement in dis-
ease activity or insulin resistance. To our knowledge,
this is the first demonstration that anti-TNF therapy
may improve insulin resistance in patients with active
RA by reversing defects in the phosphorylation/activa-
tion status of the insulin signaling pathway.
To determine whether the observed improvements in
insulin resistance and phosphorylation status of IRS-1
and AKT are directly linked to TNF blockade or are
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secondary to reduction in disease activity and inflamma-
tion, we studied seven patients with RA, who received
abatacept (CTLA4.Ig) due to high disease activity.
Patients treated with abatacept did not demonstrate
reduction in HOMA-IR levels over the 12-week study
period despite improvement in disease activity, nor did
they display any consistent alterations in p-Ser312 IRS-1
and p-AKT levels. It should be noted, however, that
these observations are limited to a small number of
patients and further documentation in a larger cohort
will be required. Moreover, it may be argued that the
duration of the study was too short to capture the meta-
bolic effects of abatacept treatment, or that we did not
evaluate changes in other molecules implicated in insu-
lin resistance such as expression of the protein-tyrosine
phosphatase (PTP)-1B or the glucose transporter
(GLUT)-4 [32].
Although our results suggest a beneficial effect of anti-
TNF treatment on insulin signaling in RA patients with
high insulin resistance, the clinical importance of such
treatment in reducing risk of cardiovascular disease in
the long term remains to be determined. In the interim,
clinical decisions for initiation of anti-TNF or other bio-
logic agents in RA should be based on disease activity
and severity indices [40]. To this end, according to the
existing EULAR recommendations, ‘adequate control of
disease activity is necessary to lower the cardiovascular
disease risk’ in RA patients [41]. Consequently, anti-
TNF agents may be preferred as first-line biologic treat-
ment in patients with active RA and high inflammatory
burden, and metabolic abnormalities or insulin
resistance.
Conclusions
In summary, we found that 12 weeks of treatment with
anti-TNF agents may improve insulin resistance in
patients with active RA and high insulin resistance.
Treatment with anti-TNF was shown to restore the
phosphorylation status of Ser312-IRS-1 and AKT, which
are important mediators in the insulin signaling cascade.
The impact of these biochemical changes in modifying
the burden of cardiovascular disease in patients with
chronic inflammatory arthritis remains to be seen.
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